Chlamydia trachomatis: when the virulence-associated genome backbone imports a prevalence-associated major antigen signature by Borges, Vítor et al.
1
Chlamydia trachomatis: when the virulence- associated 
genome backbone imports a prevalence- associated major 
antigen signature
Vítor Borges1, Dora Cordeiro2, Ana Isabel Salas2, Zohra Lodhia2, Cristina Correia2, Joana Isidro1, Cândida Fernandes3, 
Ana Maria Rodrigues3, Jacinta Azevedo4, João Alves4, João Roxo5, Miguel Rocha5, Rita Côrte- Real3, Luís Vieira6, Maria 
José Borrego2,* and João Paulo Gomes1,*
RESEARCH ARTICLE
Borges et al., Microbial Genomics 2019;5
DOI 10.1099/mgen.0.000313
Received 23 May 2019; Accepted 18 October 2019; Published 07 November 2019
Author affiliations: 1Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health, Lisbon, Portugal; 2National Reference 
Laboratory (NRL) for Curable Sexually Transmitted Infections (STIs), National Institute of Health, Lisbon, Portugal; 3Sexually Transmitted Diseases Clinic, 
Dermatovenereology Department, Central Lisbon University Hospital Centre (CHULC), Lisbon, Portugal; 4Sexually Transmitted Diseases Clinic, Lapa 
Health Centre, Lisbon, Portugal; 5CheckpointLX, Grupo de Ativistas em Tratamentos, Lisboa, Portugal; 6Innovation and Technology Unit, Department of 
Human Genetics, National Institute of Health, Lisbon, Portugal.
*Correspondence: Maria José Borrego,  M. Jose. Borrego@ insa. min- saude. pt; João Paulo Gomes,  j. paulo. gomes@ insa. min- saude. pt
Keywords: Chlamydia trachomatis; lymphogranuloma venereum (LGV); recombination; ompA; inter- clade exchange; outbreak.
Abbreviations: ENA, European Nucleotide Archive; HIV, human immunodeficiency virus; LGV, lymphogranuloma venereum; MSM, men who have sex 
with men; NAAT, nucleic acid amplification test; NCBI, National Center for Biotechnology Information; NIH, National Institute of Health; NRL, National 
Reference Laboratory; STI, sexually transmitted infection; VD, variable domain; WGS, whole- genome sequencing.
Sequence data was deposited in the ENA (BioProject accession number PRJEB32243).
Data statement: All supporting data, code and protocols have been provided within the article or through supplementary data files. Two supplementary 
figures and two supplementary tables are available with the online version of this article.
000313 © 2019 The Authors
This is an open- access article distributed under the terms of the Creative Commons Attribution NonCommercial License.
Abstract
Chlamydia trachomatis is the most prevalent sexually transmitted bacterium worldwide and the causative agent of trachoma. 
Its strains are classified according to their ompA genotypes, which are strongly linked to differential tissue tropism and disease 
outcomes [ocular disease, urogenital disease and lymphogranuloma venereum (LGV)]. While the genome- based species phylo-
genetic tree presents four main clades correlating with tropism/prevalence, namely ocular, LGV, urogenital T1 (more prevalent 
genotypes) and urogenital T2 (less prevalent genotypes), inter- clade exchange of ompA is considered a rare phenomenon 
probably mediating marked tropism alterations. An LGV epidemic, associated with the clonal expansion of the L2b genotype, 
has emerged in the last few decades, raising concerns particularly due to its atypical clinical presentation (ulcerative proctitis) 
and circulation among men who have sex with men (MSM). Here, we report an LGV outbreak, mostly affecting human immu-
nodeficiency virus- positive MSM engaging in high- risk sexual practices, caused by an L2b strain with a rather unique non- LGV 
ompA signature that precluded the laboratory notification of this outbreak as LGV. C. trachomatis whole- genome capture and 
sequencing directly from clinical samples was applied to deeply characterize the genomic backbone of this novel LGV outbreak- 
causing clone. It revealed a chimeric genome structure due to the genetic transfer of ompA and four neighbouring genes from 
a serovar D/Da strain, likely possessing the genomic backbone associated with the more prevalent urogenital genotypes (T1 
clade), to an LGV (L2b) strain. The hybrid L2b/D- Da strain presents the adhesin and immunodominant antigen MOMP (major 
outer membrane protein) (encoded by ompA) with an epitope repertoire typical of non- invasive genital strains, while keeping the 
genome- dispersed virulence fingerprint of a classical LGV strain. As previously reported for inter- clade ompA exchange among 
non- LGV clades, this novel C. trachomatis genomic mosaic involving a contemporary epidemiologically and clinically relevant 
LGV strain may have implications on its transmission, tissue tropism and pathogenic capabilities. The emergence of variants 
with epidemic and pathogenic potential highlights the need for more focused surveillance strategies to capture C. trachomatis 
evolution in action.
DATA SummARy
Chlamydia trachomatis- specific reads and assembled 
genome generated in this study were deposited in the 
European Nucleotide Archive (ENA) (BioProject accession no. 
PRJEB32243; www. ebi. ac. uk/ ena/ data/ view/ PRJEB32243). 
ENA accession numbers are included in Table S1 (available 
2
Borges et al., Microbial Genomics 2019;5
with the online version of this article). The L2- L2b/D- Da 
hybrid ompA sequence was also deposited in the National 
Center for Biotechnology Information under the accession 
number MN094864.
InTRoDuCTIon
Sexually transmitted infections (STIs) are a global major 
public- health concern, resulting in significant morbidity and 
health- care costs. The World Health Organization (WHO) 
predicts that more than 1 million curable STIs occur each 
day, with an estimate of 127 million new cases of Chlamydia 
trachomatis infections in 2016 [1]. Lymphogranuloma 
venereum (LGV), one of the C. trachomatis- associated 
diseases of high concern, emerged in European countries 
since 2003, contrasting with the nearly ‘inexistent’ LGV cases 
detected until the new millennium [2–7]. A real estimate of 
LGV infection rates in Europe cannot be robustly performed. 
In fact, many LGV surveillance systems do not generate data 
that are considered representative of the national population 
(although reporting of LGV infection is compulsory in most 
countries with comprehensive surveillance systems), and 
there are significant differences in the capacity to identify 
the LGV- causing C. trachomatis lineages [8, 9]. This context 
represents an enhanced challenge for both health- care 
providers and public- health authorities, since the current 
recommended treatment for LGV differs from the one for 
non- LGV C. trachomatis infections [8, 10]. In contrast to 
the classical LGV presentation (i.e. inguinal syndrome with 
painful lymphadenopathy), current LGV cases are essentially 
manifested by proctitis characterized by severe symptoms, 
such as anorectal pain, rectal tenesmus, haemopurulent 
discharge and bleeding. This ‘anorectal syndrome’ mostly 
afflicts men who have sex with men (MSM), normally 
co- infected with human immunodeficiency virus (HIV) and 
other STIs [3, 4, 8]. The proctitis- associated LGV epidemic is 
being primarily caused by strains from the LGV genotype L2b 
[11], although some countries have been reporting increasing 
cases associated with the L2 genotype [12–14]. Genotyping of 
C. trachomatis relies on the polymorphism of the ompA gene, 
which encodes the major outer membrane protein (MOMP), 
its main antigen. The ompA- based phylogeny is incongruent 
with the genome- based species tree, but ompA genotype clas-
sification strongly correlates with tissue tropism and disease 
outcome, as genotypes A–C are strongly associated with the 
trachoma, genotypes D–K with urogenital infection and 
genotypes L1–L3 with LGV. This genotype grouping is gener-
ally reflected in the genome- based species tree, presenting 
a well- established topology with four main clades: ocular, 
LGV, urogenital T1 (enrolling clinically prevalent genotypes 
– mostly E and F) and urogenital T2 (involving less- prevalent 
genotypes) [15, 16]. Recombination is a main driver of 
contemporary C. trachomatis evolution and diversification, 
mainly leading to extensive intra- clade homologous exchange 
of genomic regions (including ompA), since genetic exchange 
between strains with the same tissue tropism is more likely to 
occur [15–18]. Inter- clade recombination is less marked. A 
relevant example enrolling the LGV clade concerns the report 
of a severe clinical case caused by an L2 strain that imported 
several genome- dispersed regions from a D urogenital strain, 
although ompA exchange was not observed and no further 
cases were reported [19]. In fact, the exchange of ompA 
between strains from the three disease groups (i.e. ocular, 
genital and LGV) is considered a rare phenomenon among 
contemporary clinical strains [16] and is believed to mediate 
marked tropism alterations [16, 20].
In the present study, we report an ongoing C. trachomatis 
outbreak caused by a recombinant strain with a rather unique 
genome make- up, presenting the adhesin and immuno-
dominant antigen MOMP with an epitope repertoire typical 
of non- invasive genital strains, while keeping the genome- 
dispersed virulence fingerprint of a classical LGV (L2b) 
strain. This constitutes what is believed to be the first report 
of a contemporary inter- clade import of ompA to an LGV 
strain with high clinical and public- health relevance.
mETHoDS
C. trachomatis molecular diagnosis and surveillance
The National Reference Laboratory (NRL) for Curable STIs 
of Portugal, hosted at the National Institute of Health (NIH) 
Impact Statement
It is known that subtle evolutionary changes of patho-
gens may lead to rapid modifications in diagnosis and 
surveillance strategies. Here, we report the emergence 
of an outbreak- causing Chlamydia trachomatis strain 
with a novel recombinant genome make- up including a 
chimeric ompA (the classical typing gene and the main 
antigen/adhesin- encoding gene) genotype. The emer-
gence of such a recombinant variant may have impact 
mainly at two levels. First, the hybrid L2b/D- Da ompA 
genotype precluded the compulsory national laboratory 
notification of the outbreak cases as lymphogranuloma 
venereum (LGV) cases. This challenges the current legal 
criteria for LGV notification (established by the Euro-
pean Commission and adopted by Portugal), and justifies 
the usage of broader multi- loci typing techniques in C. 
trachomatis outbreak detection, monitoring and control. 
Secondly, this genomic variant underlies a singular C. 
trachomatis diversification step, which is marked by the 
recombination- driven import of a non- LGV ompA (and 
four neighbouring genes) by an LGV strain with high 
clinical and public- health relevance (i.e. the worldwide 
disseminated proctitis- associated C. trachomatis L2b 
clone). Considering the strong correlation between ompA 
genotypes (and the mutational signature of the neigh-
bouring genes) and C. trachomatis tropism/prevalence, it 
can be hypothesized that this variant may harbour modi-
fied transmission, tissue tropism and pathogenic capa-
bilities.
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Doutor Ricardo Jorge (Lisbon, Portugal), acts as a routine 
C. trachomatis diagnostic laboratory for NIH clients. 
These are members of the public attending the NIH, and 
specific risk populations (MSM, migrants, transsexuals and 
commercial sex workers) attending STIs clinics. The NRL is 
also responsible for nationwide laboratory surveillance of 
C. trachomatis. In this context, the NRL routinely performs 
the molecular characterization of all C. trachomatis strains, 
either identified in the NRL itself or by any Portuguese 
laboratory.
C. trachomatis molecular diagnosis was performed by using 
a dual- target (chromosome plus plasmid) commercial 
nucleic acid amplification test (NAAT) (Cobas 4800 CT/NG 
Roche Diagnostics), following the manufacturer’s instruc-
tions. Anorectal samples tested as C. trachomatis positive 
by the first- line NAAT test were subsequently subjected 
to a rapid LGV discriminatory NAAT (CLART STIs from 
Genomica and/or Allplex genital ulcer assay from Seegene, 
both targeting the pmpH gene), following European Guide-
lines on the Management of LGV and despite the lack of 
thorough validation of these tests [8]. Also, DNA samples 
from all C. trachomatis- positive specimens (identified either 
in the NRL or in nationwide laboratories) are routinely 
subjected to ompA sequencing- based genotyping, since 
LGV laboratory notification is compulsory in Portugal and 
requires molecular confirmation of ompA genotypes L1–L3 
[21]. Briefly, PCR and nested PCR were performed using 
primers NLO and NRO, and primers PCTM3 and SERO2A 
[22], respectively, as previously described [23], followed by 
partial nucleotide sequencing of the ~1010 bp PCR product 
using primer ompA-1 (5′-TTA TGA TCG ACG GAA TTC 
T-3′), BigDye terminator v1.1 and capillary sequencing 
(3130XL Genetic Analyzer; Applied Biosystems). ompA 
genotypes are currently determined by blastn- based 
comparison (using the ABRIcate tool) [24] with a custom 
database enrolling reference and variant sequences of all 
ompA genotypes [25]. mega software (version 7) [26] is 
additionally applied for fine- tuned sequence inspection and 
curation, alignment and phylogenetic reconstructions.
Targeted C. trachomatis whole-genome capture and 
sequencing directly from clinical samples
In order to potentiate the success of the culture- independent 
whole- genome sequencing (WGS) of C. trachomatis, diag-
nostic DNA samples positive for the novel hybrid L2b/D-
 Da ompA genotype were preliminarily subjected to dsDNA 
quantification (using Qubit; ThermoFisher Scientific) and 
subsequent absolute real- time quantification of both the 
number of C. trachomatis (targeting the single- copy ompA) 
and human genome copies (targeting β-actin), as previously 
described [27]. Samples selected (n=12) for targeted WGS 
had an amount of DNA above the minimum required for 
library preparation (>10 ng in 7 µl) and a number of C. 
trachomatis copies in the SureSelect XT HS (Agilent Technolo-
gies) input volume (7 μl) above 4×103. Since the success 
of culture- independent targeted WGS does not seem to 
depend on the degree of human DNA content [28], this 
measure did not constitute a rigid criterion (although it 
was taken into account to discriminate samples with low 
C. trachomatis load) (Table S1).
C. trachomatis whole- genome capture and sequencing 
directly from selected DNA samples was performed using 
Agilent Technologies’ SureSelect XT HS target enrichment 
system for Illumina paired- end multiplexed sequencing 
library protocol (G9702-90000, version C0, September 
2018; Agilent Technologies) upon enzymatic fragmentation 
with SureSelect XT HS and XT low input enzymatic fragmen-
tation kit (G9702-90050, Revision A0, September 2018; 
Agilent Technologies), according to the manufacturer’s 
instructions. For this, RNA oligonucleotide baits (120 bp in 
size; a total of 33 619 baits) were bioinformatically designed 
by our group to span the C. trachomatis chromosome 
and plasmid, and were further ordered for production in 
Agilent Technologies. Our custom bait design accounted 
for the main genetic variability among the four clades of 
the C. trachomatis species tree [15, 16], where baits with 
homology to the human genome (after discontiguous 
MegaBlast searches against the Human Genomic +Tran-
script database) were excluded. After library quantification 
and normalization (using the Fragment Analyzer with the 
HS NGS fragment kit; Advanced Analytical Technologies), 
C. trachomatis- enriched libraries were subjected to cluster 
generation and paired- end sequencing (2×150 bp) using 
MiSeq equipment (Illumina), according to the manufac-
turer’s instructions.
Bioinformatics
In order to confirm the outbreak and characterize the 
genomic backbone and mosaicism of the hybrid L2b/D- Da 
C. trachomatis strain, the following bioinformatics activities 
were conducted: (i) reads’ quality analysis and cleaning/
improvement, de novo genome assembly and post- assembly 
optimization using the integrative pipeline INNUca 
version 4.0.1 [29]; (ii) reference- based mapping and SNP/
indel analysis against representative genome sequences of 
both the worldwide disseminated proctitis- associated C. 
trachomatis L2b strain [L2b/UCH-1/proctitis; National 
Center for Biotechnology Information (NCBI) accession 
numbers AM884177.2/NC_010280.2 for the chromo-
some and AM886279.1 for the plasmid] and the detected 
L2b/D- Da C. trachomatis strain [strain Ct_L2b/D_PT05; 
European Nucleotide Archive (ENA) accession number 
CAAKND010000000] using Snippy version 4.1.0 [30]; (iii) 
whole- genome alignment and inspection using Mauve 
software version 2.3.1 [31]; (iv) coreSNP- based alignment 
and recombination inspection/visualization using Parsnp 
and Gingr tools available at the Harvest suite, respectively 
[32]; (v) integration of the hybrid L2b/D C. trachomatis 
strain in the ompA- based and genome- based species trees 
[15] by constructing approximately- maximum- likelihood 
phylogenetic trees using the double- precision mode of Fast-
Tree2 under the general time- reversible (GTR) model (1000 
bootstraps) [33]; and (vi) locus- based sequence alignment 
and manipulation using mega software (version 7) [26].
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Fig. 1. Confirmed cases of the outbreak- causing hybrid L2b/D- Da C. trachomatis strain. Schematic summary of the clinical data, co- 
infections, risk behaviours and laboratory typing results.
RESuLTS
Detection of a novel hybrid L2b/D-Da ompA 
genotype causing a proctitis-associated LGV 
outbreak
On behalf of the national laboratory surveillance of C. 
trachomatis, the Portuguese NRL for curable STIs performs 
ompA sequencing- based genotyping, not only to monitor 
the genetic diversity of circulating strains, but also to comply 
with the legislation requirements for LGV laboratory notifi-
cation (i.e. detection of L1–L3 genotypes), which has been 
compulsory in Portugal since 2017. Since that year, the NRL 
started detecting clinical specimens tested as LGV posi-
tive by a rapid discriminatory commercial NAAT (CLART 
STIs) that were not confirmed by classic ompA genotyping 
later on. As such, we initially interpreted the incongruent 
results as a failure of the commercial test. However, given 
the continuous emergence of these discrepant cases, we 
retrospectively performed an alternative commercial test 
(Allplex genital ulcer assay), which confirmed the prior 
LGV- positive results. We proceeded with the inspection 
of ompA and observed that all cases had an identical ompA 
sequence phylogenetically placed among D/Da strains. Still, 
a fine scrutiny of the sequence revealed an L2- L2b/D- Da 
hybrid profile, i.e. while the first 302 bp match to ompA L2/
L2b reference sequences (L2b/UCH-1/proctitis; GenBank 
accession number AM884177.1; L2/434/BU, GenBank 
accession number AM884176.1), the region spanning the 
366–1182 bp revealed a D/Da profile matching the reference 
strain D/UW-3 and a Da variant (CS-908/07) circulating in 
Portugal [34] (GenBank accession numbers NC_000117.1 
and FJ943521, respectively). The conserved region between 
the 5′−3′ gene position 303–365 was estimated as the 
recombination crossover region. The L2- L2b/D- Da hybrid 
ompA sequence was deposited at the NCBI under the acces-
sion number MN094864.
Twenty- five cases have been detected (the first case in 
April 2017). The novel hybrid LGV genotype represents 
12.5 % (10/80) and 16.5 % (15/91) of all LGV cases (i.e. 
classical LGV genotypes plus the hybrid L2- L2b/D- Da 
hybrid genotype) detected in the Portuguese NIH during 
2017 and 2018, respectively. These represent about 20 % 
of all C. trachomatis- positive specimens already subjected 
to ompA genotyping in the Portuguese NRL in both 2017 
(80/405) and 2018 (91/484). Of note, the hybrid L2- L2b/D-
 Da genotype constitutes about half (in 2017) and one 
third (in 2018) of the number of cases of the classical 
L2b genotype associated with worldwide proctitis- related 
C. trachomatis epidemics occurring since 2003. All 25 
specimens (most anorectal swabs) were collected from 
MSM presenting similar symptoms and clinical features 
(e.g. rectal syndrome, rectal pain, rectal tenesmus, anal 
discharge, rectal bleeding) (Fig. 1). Sexually transmitted 
bacterial co- infections were diagnosed for most patients, 
especially Neisseria gonorrhoeae (18 out the 25 patients). 
HIV status was available for 17 patients, 16 of which 
being positive. Multiple partners (>10 in last 6 months) 
and engaging in chemsex, as well as involvement with 
international sexual networks, were also reported (Fig. 1). 
Although all the health centres where cases were detected 
do not have harmonized behavioural- data collection 
procedures, hampering the identification of common sex 
venues or social events, known risk factors for rectal LGV, 
such as practices of fisting, douching and group sex in the 
last 12 months were reported for many MSM.
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Fig. 2. Phylogenetic integration of the hybrid L2b/D- Da outbreak- causing C. trachomatis strain in the genome- based species tree (a), 
ompA tree (b) and concatenated CT677–CT680- based tree (c). Represented strains reflect the species phylogenetic diversity [15] and 
are coloured by the genome- based phylogenetic clade (ocular, yellow; prevalent genital – T1, red; non- prevalent genital – T2, green; and 
LGV, black), as marked in (a).
The real number of cases cannot be predicted due to lack of 
geographical coverage of the national surveillance program. 
Furthermore, there is a delay associated with the genotyping 
procedure (it is performed in batches and not in a real- time 
fashion) and the genotyping technique frequently fails (in 
about 30 % of the assays). The last case was detected on 10th 
November 2018.
Genome-based outbreak confirmation
In order to confirm the outbreak and characterize the 
genomic backbone of the C. trachomatis causative strain, 
RNA baits- based targeted genome capture and sequencing 
was performed directly from diagnostic DNA samples (12 
samples were selected upon bacterial load quantification 
through quantitative PCR). Five complete or near- complete 
genomes were successfully sequenced (a representative 
assembly was deposited in ENA/NCBI under the accession 
number CAAKND010000000/CAAKND01) (Table S1). The 
phylogenetic integration of the hybrid C. trachomatis strain 
in the frame of well- established genome- based species trees 
[15] places it in the LGV clade, namely within the monophy-
letic branch reflecting the clonal expansion of the globally 
disseminated proctitis- associated C. trachomatis L2b lineage 
(Fig. 2a). This contrasts with its position among serovar 
D/Da strains in ompA phylogeny (Fig. 2b), and strongly 
supports a scenario of recombination- driven inter- clade 
ompA exchange (detailed in the next section of Results), 
where the epidemic proctitis- associated L2b lineage was the 
most likely recipient strain. SNP/indel analysis of the hybrid 
L2b/D- Da complete (or near- complete) genomes against 
the classical L2b representative genome (L2b/UCH-1/
proctitis strain) confirmed the high genetic relatedness 
with the parental- like strain and the clonality of the hybrid 
strains. In fact, apart from a single high SNP density peak 
observed in the recombinant region (enrolling ompA), only 
35 variant sites (involving SNPs and small indels spanned 
throughout the chromosome) were detected among the five 
hybrid L2b/D- Da strains when compared with L2b/UCH-1/
proctitis (Fig. 3a; Table S2). No differences were found in 
the plasmid. The L2b genomic backbone and recombination 
event could be also verified for the seven hybrid strains 
with partial genome data by the detection of other genetic 
fingerprints beyond the hybrid ompA profile detected by 
classical genotyping. These included the detection of SNP/
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Fig. 3. Genome backbone and mosaic structure of the outbreak- associated C. trachomatis L2b/D- Da recombinant strain. (a) Genome 
backbone and recombination analysis of the L2b/D- Da C. trachomatis strain. The graph shows the number of genetic differences (SNPs 
and indels) detected among five complete or near- complete genomes of outbreak- associated L2b/D- Da clones when comparing with 
the genome (chromosome plus plasmid) sequence of the L2b/UCH-1/proctitis strain, which is a representative strain of the worldwide 
disseminated proctitis- associated outbreak of C. trachomatis L2b (a probable parental- like strain) occurring since 2003 (GenBank 
accession numbers: AM884177.2/NC_010280.2 for chromosome and AM886279.1 for the plasmid). Polymorphism is displayed as 
variant sites (SNPs or indels) in a window size and a step size of 10 000 bp each, where variants introduced by the main recombination 
event are highlighted in red. The 100 % conserved plasmid is present at the right side of the blue dashed line. Polymorphisms outside the 
recombinant fragment are detailed in Table S2. (b) Detail of the recombination event. The L2b/D- Da C. trachomatis strain is a recombinant 
strain resulting from the genetic import of the a ~4.2 kbp genomic fragment from a non- LGV D/Da strain (most likely belonging to T1 
clade) by a typical proctitis- associated L2b strain. The recombination fragment (highlighted in red by both boxes and coloured genes) 
enrols ~75 % of CT681/ompA and four entire genes (CT677/frr, CT678/pyrH, CT679/tsf, CT680/rpsB) (positions 55221–59461 in the L2b/
UCH-1 chromosome). Estimated recombination crossovers most likely involved the two following regions (shaded in orange): (i) a region 
with two contiguous tRNAs located between CT676 and CT677/rrf; and (ii) a conserved region (among serogroup B serovars: B/Ba, D/Da, 
E, L1 and L2) within ompA (5’- 3’ gene position 303-365). For scheme simplification, the core- genome- based phylogenetic reconstruction 
enrols sequences from C. trachomatis strains representing the main clades of the species tree [15] and from five outbreak- associated 
L2b/D- Da clones. Vertical pink lines reflect SNPs against the chromosome sequence of the parental- like L2b/UCH-1/proctitis strain 
(region spanning positions 54500–60000 bp; accession numbers AM884177.2/NC_010280.2) (highlighted by horizontal light blue lines). 
Gene orientation and annotation refers to the firstly released C. trachomatis genome, D/UW-3/CX strain (GenBank accession number 
NC_000117). (c) Schematic representation of the topology sketch of the recombinant MOMP, where the L2/L2b- like and D/Da- like non- 
transmembrane parts of the protein are coloured in black and red, respectively. MOMP is oriented from N- terminal to C- terminal (left 
to right). L1- L8 indicates protein loops (L) facing the outside, and include the four VDs (VDI–VDIV) of MOMP (shaded in blue). Amino acid 
sequence is detailed in Fig. S2. MOMP structure was drawn based on data from published work [25, 62].
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indel markers of the hybrid strain, the detection of the L2b 
plasmid and/or identification of sequencing reads 100 % 
matching to the non- LGV recombinant fragment (Tables 
S1 and S2). Of note, similarly to the scenario observed 
during the clonal expansion of the epidemic L2b lineage 
[35], the SNP/indel- based (micro)evolutionary segregation 
and discreet diversification of the hybrid strain is marked by 
non- synonymous mutations targeting several genes poten-
tially linked to pathoadaptation, such as genes encoding 
inclusion membrane proteins (e.g. CT223 and CT383), 
type III secretion system effectors (e.g. CT456/Tarp) and 
surface proteins (e.g. CT242/ompH, CT270/pbp3) (Table 
S2). Curiously, some clones harbour a frameshift deletion in 
CT157 (CTL0413 in the reference strain L2/434/Bu), which 
encodes a phospholipase D (PLD) protein. This represents 
the inactivation of an additional PLD protein, besides the 
other PLD pseudogenes that seem to characterize the LGV 
strains [11]. It is also noteworthy that several SNP/indels 
distinguishing the hybrid strain from the L2b/UCH-1/proc-
titis are homoplasic (Table S2) as they occur in different 
branches of the C. trachomatis species tree.
Characterization of the genome mosaicism of the 
outbreak-related L2b/D-Da recombinant
Detailed analysis of the detected genetic mosaicism supports 
that the outbreak- causing L2b/D- Da hybrid C. trachomatis 
strain resulted from the genetic transfer of a ~4.2 kbp genomic 
fragment (transferring 240 SNPs, 76 of which were within 
ompA) from a D/Da strain to a typical proctitis- associated 
L2b strain (Figs 3a,b and S1). The non- LGV parental strain 
was most likely a D/Da strain with E/F- like genomic back-
bone, i.e. belonging to clade T1 of the species tree (which 
involves prevalent genotypes) (Figs  2 and 3b). In fact, 
although NCBI blast analyses of the imported fragment 
found no single genome with 100 % similarity, the ‘top’ hits 
(query cover=100 %; identity >99.75 %) are serovar D/Da 
strains reported to belong to clade T1: D/13–96 [16, 36], D/
SotonD1 [15], D/SQ29 and D/SQ32 [37]. The T1 donor back-
bone is also strongly supported by the existence of multiple 
SNVs within the transferred region perfectly segregating 
T1 strains and also SNVs that are exclusive of serovar D/
Da strains with a E/F- like genome profile (Figs 2c and 3b). 
The recombinant fragment (position 55221–59461 in the 
L2b/UCH-1 chromosome) enrols ~75 % of CT681/ompA, 
which encodes the major C. trachomatis antigen (MOMP), 
and four entire genes (CT677/rrf, CT678/pyrH, CT679/tsf, 
CT680/rpsB) located downstream from ompA. Estimated 
recombination crossovers most likely involved the two 
following regions: (i) a region with two contiguous tRNAs 
located downstream from CT677/rrf; and (ii) a conserved 
region (among serogroup B serovars: B/Ba, D/Da, E, L1 and 
L2) within ompA (5′−3′ gene position 303–365). Of note, the 
latter breakpoint region has been also involved in the partial 
import of ocular ompA by strains with urogenital backbone 
associated with ocular infections [16, 20]. The recombinant 
L2b/D- Da MOMP displays a total of 19 aa replacements and 
a 1 aa insertion when compared with the parental- like L2b 
MOMP, with 18 of the amino acid variants falling within 
surface- exposed epitope- enriched highly variable domains 
(VDs) (Fig. S2). In fact, the recombination event yielded a 
new combination of epitopes in the C. trachomatis immuno-
dominant antigen, MOMP, mixing serovar L2/L2b epitopes 
(VDI region) and serovar D/Da- like epitopes (from VDII to 
VDIV) (Figs 3c and S2).
DISCuSSIon
WGS- based typing is still not applicable for C. trachomatis 
routine surveillance, despite the need for timely characteriza-
tion of circulating types and variants to disclose transmission 
chains, guide therapies and identify emerging public- health 
harm. However, the recent history of C. trachomatis infections 
illustrates how the dynamic pathogen evolution (rather than 
the availability of technological advances) prompts the adop-
tion of important modifications in diagnosis, surveillance and 
therapeutic strategies. The first relevant example of ‘evolution 
in action’ with impact on molecular diagnosis/surveillance 
was the emergence of a C. trachomatis variant, detected in 
2006 in Sweden, with a deletion in the plasmid region targeted 
by widespread commercial NAATs [38]. Retrospective studies 
revealed that this variant had been in circulation at least since 
2001 and displayed a rapid spread (reaching in a few years 
64 % of all diagnosis in Sweden) due to diagnostic failure 
and a consequent lack of treatment [39, 40]. This situation 
led to a rapid switch to different molecular diagnostics tests, 
while leading to the replacement of the single target tests in 
question by tests that target both the plasmid and the chromo-
some [41]. More recently, a C. trachomatis variant detected 
in Finland was found to yield false- negative results in over 
160 cases, potentially due to a nucleotide substitution in the 
sequence targeted by the diagnostic test [42].
The evolution of C. trachomatis is expectedly potentiated by 
increasing human population density and mobility, as well 
as by changes in sexual networks, which enhance the spread 
and admixture of strains. Accordingly, the global emergence 
of the successful MSM- associated proctitis- related L2b clone 
implicated the modification of international guidelines for 
C. trachomatis molecular identification/typing towards the 
adoption of tests targeting LGV- specific loci and differential 
treatment of LGV cases [8, 41]. The unique character of the 
outbreak- causing L2b/D- Da recombinant strain reported in 
the present study may lead to an ‘erroneous’ classification and 
potentially incorrect treatment if only the conventional ompA 
typing is performed, because ompA phylogeny places this 
hybrid strain among serovar D/Da strains (Fig. 2). Although 
commercial NAATs for rapid LGV/non- LGV differentiation 
were proficient in detecting these recombinant strains as LGV, 
they are not widely available and still lack validation [8, 43]. 
A laboratory sub- notification of LGV cases (compulsory in 
multiple countries [9]) may also occur, as ompA genotyping is 
still required to comply with the Commission Implementing 
Decision (EU) 2018/945 of 22 June 2018 [44], which demands 
L1, L2 or L3 identification as criteria for a confirmed LGV 
case. For example, in Portugal, where LGV laboratory 
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notification is compulsory and LGV case definition [21] is 
in compliance with the European Union legislation, these 
outbreak- associated cases cannot be formally notified as 
LGV. This has already triggered a still ongoing revision of 
the laboratory LGV notification criteria. Altogether, this situ-
ation may facilitate the spread of the hybrid outbreak strain 
especially due to its circulation among MSM (most of them 
co- infected with HIV and other STI agents), who often report 
a sexual behaviour marked by engaging in chemsex and, in 
some cases, involvement in international sexual networks. 
Considering this methodological and epidemiological 
context, one can hypothesize that the outbreak has already 
crossed borders, although remained unnoticed. This whole 
scenario highlights the need to revise laboratory methods for 
notification, and supports the international recommendations 
to target LGV- specific genome loci for detecting, monitoring 
and controlling LGV outbreaks. Several MLST- like systems 
capable of LGV- strain identification have been described 
(e.g. [45–48]) but none of them has been broadly adopted 
by the scientific community. Curiously, in silico extraction 
of MLST profiles using the three schemes currently available 
at PubMLST [https:// pubmlst. org/ (accessed 15 May 2019)] 
showed that the recombinant L2b/D- Da strain cannot be 
distinguished from the parental- like L2b/UCH-1/proctitis 
lineage by applying these MLST strategies [belonging to ST44 
(Chlamydiales scheme [46]), ST1 (C. trachomatis scheme 
[47]) and ST58 (C. trachomatis Uppsala scheme [45])]. As 
such, the present outbreak further supports the application of 
multi- loci typing strategies in addition to ompA genotyping. 
From a clinical point of view, this specific epidemic reinforces 
the notion that MSM (especially those who are HIV- positive) 
should be routinely screened for oral, urethral and anal C. 
trachomatis infection. Voluntary partner notification and 
treatment may also be considered due to the possible sexual 
network (sex abroad and chemsex). From another perspective, 
second generation surveillance for LGV (e.g. NRL- centralized 
integration of both microbiological and demographic/behav-
ioural data, safeguarding the appropriate ethical and social 
issues) would be advisable in order to track both the ‘evolu-
tion’ and ‘context’ of C. trachomatis (namely LGV) epidemics. 
For example, in this outbreak, a harmonized behavioural 
survey among the enrolled STI clinics could have yielded 
more complete reports about practices of fisting, douching 
and group sex in the last 12 months, which are known risk 
factors for rectal LGV [49]. The latter were actually reported 
by most patients attending one of the clinics where this data 
are systematically collected.
The inter- strain exchange of the whole or part of the 
ompA gene is a natural phenomenon in C. trachomatis 
[15–18, 20, 50–52]. To the best of our knowledge, in addition 
to the known ancient ompA diversification (leading to the C. 
trachomatis ompA- based phylogenetic grouping being incon-
gruent with the genome- wide phylogenetic topology) [15], 
the present study provides the first report of an epidemiologi-
cally and clinically relevant hybrid strain presenting a clas-
sical LGV chromosome backbone, while harbouring most 
of the major antigen (MOMP) from a non- LGV strain. This 
evolutionary step is not surprising in the epidemiological 
and demographical context it emerged. In fact, the MSM- 
associated worldwide epidemics of L2b (occurring during 
the last two decades) potentiate co- infection with highly 
prevalent urogenital strains (e.g. T1 clade), which are usually 
associated with asymptomatic infections, favouring multiple 
rounds of infections and co- infections. Besides the main 
recombination event, the hybrid strain also revealed discreet 
genome- dispersed homoplasies that further corroborate a 
scenario of recurrent exchange of genetic material with other 
non- LGV strains. This is a microevolutionary mechanism 
occurring in parallel with the fixation of de novo mutations 
mostly affecting host- interacting proteins with a potential 
role in pathoadaptation (Table S2). The observed genomic 
mosaicism results in not only a new combination of MOMP 
epitopes (mixing D/Da- like and L2/L2b- like epitopes within 
MOMP) (Figs 3 and S2), but also a novel antigenic composi-
tion at the proteome level. In fact, most MOMP epitopes 
(targeted by both T- and B- cells) belong to strains typically 
associated with non- invasive genital tropism, whereas the 
remaining antigen repertoire (e.g. polymorphic membrane 
proteins – Pmps; chlamydial protease- like activity factor – 
CPAF; inclusion membrane proteins – Incs; OmcB) [11, 53] 
is typical of LGV strains causing anorectal and/or inguinal 
syndromes. We can hypothesize that this novel MOMP 
chimeric structure influences the strain’s ability to deal with 
the immunological response, as even modest alterations in 
the immunodominant MOMP may substantially change 
C. trachomatis antigenic presentation [54–56]. Beyond the 
potential impact on the interaction with the host immune 
system, it is conceivable that other bacterial functions are 
also affected, possibly influencing pathogenesis. In fact, the 
immunodominant MOMP, which constitutes about 60 % 
of the membrane dry weight [57], is also a porin [58] and 
adhesin [59], which are well established host- interacting 
bacterial factors underlying differential tissue tropism. Note-
worthy is the fact that the expected role of inter- clade ompA 
exchange in mediating alterations in phenotypic and trans-
mission capabilities has been recently corroborated by the 
independent detection (in Australia and Europe) of ocular 
ompA genotypes introgression into typical urogenital strains 
(from clades T1 and T2) associated with both ocular and 
urogenital infections [16, 20]. Although the selective advan-
tage of the recombinant strain most likely relies on the novel 
signature of the hybrid MOMP, the other exchanged genes 
neighbouring ompA (CT677/rrf, CT678/pyrH, CT679/tsf, 
CT680/rpsB), which play key functional roles (in ribosome 
recycling, pyrimidine metabolism, translation elongation 
and structural ribosome constitution, respectively), may also 
contribute to an enhanced fitness. This may be particularly 
relevant considering that: (i) their mutational signature in 
the hybrid L2b/D- Da strain matches the one observed for 
prevalent clade T1 strains (i.e. strains with E/F- like genomic 
backbone); and (ii) the CT677–CT680 region shows phylo-
genetic signals of tropism and prevalence (Fig. 3c) [60, 61]. 
For example, it has been speculated that increased fitness at 
or around ompA (preventing recombination) may underlie 
the expansion of genotype E, which is in general the most 
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successful C. trachomatis genotype among STIs as suggested 
by its high prevalence and global distribution [16, 34, 61]. 
In conclusion, considering that (i) the hybrid outbreak 
strain displays a novel antigenic and adhesin fingerprint, 
while retaining the classical epidemic LGV (L2b) genome- 
dispersed virulence signature; (ii) L2b strains are capable of 
dual tropism, i.e. infection of the rectal mucosa (leading to 
proctitis) and/or dissemination through mononuclear mono-
cytes to inguinal nodes (leading to the bubonic disease LGV); 
and (iii) the presumably parental genital strain belongs to 
the T1 clade, which includes the ecologically most successful 
genital strains; one can hypothesize that the observed 
recombination- driven unique genomic backbone may 
have implications on the transmission, tissue tropism and 
pathogenic capabilities of the circulating hybrid outbreak- 
associated strain. However, a more- definitive information 
regarding the potentially enhanced phenotypic skills of the 
hybrid strain must await the detection of the hybrid L2b/D-
 Da strain from around the world, as well as in vitro and in 
vivo assays to assess host- evasion and growth characteristics.
This study reports an ongoing outbreak involving a unique 
L2b variant (with potential modified fitness) in the context 
of the parental L2b worldwide epidemics. The risk sexual 
behaviour (e.g. multiple partners, engaging in chemsex) 
and sexual network involvement enhances the likelihood of 
this outbreak to have already spread abroad, which might 
be soon confirmed if broader C. trachomatis genotyping 
strategies are followed. The non- eligibility of this outbreak as 
laboratory- confirmed LGV cases additionally highlights the 
need to revise the European Commission criteria, adopted 
by several countries, including Portugal, for LGV laboratory 
notification.
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